We’re excited to announce the first in Xconomy’s new Xcelerating Life Sciences event series convening local communities of innovators, executives, rising pioneers, entrepreneurs, investors, and scientists: Xcelerating Life Sciences San Diego will help you stay at the forefront of San Diego’s... Read more »
Startup nference has closed a $60 million Series B financing round to expand the use of its augmented intelligence platform in clinical research and drug development.
Mayo Clinic and NTT Venture Capital joined previous investors Matrix Partners and Matrix Capital Management,... Read more »
[Updated 1/22/20120, 7:17 a.m. See below.] Emendo Biotherapeutics, a company aiming to apply CRISPR gene editing to a wider range of genetic diseases, has raised $61 million in financing.
The Series B round was led by AnGes, a Japan-based... Read more »
The Department of Defense has awarded Adaptive Phage Therapeutics a $10.2 million contract to help advance its experimental therapy for the treatment of multidrug-resistant infections.
Gaithersburg, MD-based Adaptive Phage Therapeutics (APT) says it will pursue a two-year multi-site clinical trial as... Read more »
[Updated 1/15/2020, 8:51 a.m. See below.] As the nation grapples with the ongoing opioid crisis, an FDA advisory panel on Tuesday unanimously voted against recommending approval of a Nektar Therapeutics painkiller that would add a new compound to the... Read more »
Insilico Medicine on Tuesday announced that it has entered a research collaboration with Pfizer, which Insilico CEO Alex Zhavoronkov says has “one of the most advanced AI teams internally both in target identification and chemistry.”
Under the agreement, Pfizer (NYSE: PFE... Read more »
Scan the landscape of experimental medicines in development today and you’ll spot Schrödinger’s handiwork. The company’s software has helped discover compounds that are now advancing in the pipelines of several drug developers.
Schrödinger isn’t shying away from that work. But as... Read more »
Daré Bioscience launched in 2015 with the aim of assembling a portfolio of novel women’s health products intended to pique interest from major pharmaceutical companies.
Now the San Diego-based company has inked its first deal with Big Pharma, signing an agreement... Read more »